The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:93-95 July 3, 2008 Number 1
NextNext

Imiquimod for Vulvar Intraepithelial Neoplasia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by van Seters, M.
-PubMed Citation
To the Editor: Van Seters et al. (April 3 issue)1 report that regression of vulvar intraepithelial neoplasia was significantly greater in the imiquimod group than in the placebo group. However, the small number of patients treated with imiquimod (26), the low complete response rate, and the short follow-up period (1 year) do not provide support for the conclusion that imiquimod should be the first-choice treatment for vulvar intraepithelial neoplasia. Only 9 of 26 patients had complete regression of lesions at 5 months, which is not a good result as compared with surgery (either excision or vulvectomy) or laser ablation.2,3 Moreover, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.